BlueSky Immunotherapies GmbH
🇦🇹Austria
Clinical Trials
6
Active:1
Completed:2
Trial Phases
1 Phases
Phase 1:5
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Phase 1
5 (100.0%)Phase 1 Clinical Trial of FluBHPVE6E7 Immunotherapy for HPV16-Associated Oropharyngeal Cancer
Phase 1
Recruiting
- Conditions
- Oropharyngeal Squamous Cell Carcinoma (SCC)
- Interventions
- First Posted Date
- 2024-09-10
- Last Posted Date
- 2024-09-10
- Lead Sponsor
- BlueSky Immunotherapies GmbH
- Target Recruit Count
- 12
- Registration Number
- NCT06589609
- Locations
- 🇦🇹
Medical University Vienna, Vienna, Austria
Phase 1 Dose-escalation Study of FluBHPVE6E7 in HPV16-infected Women
Phase 1
Recruiting
- Conditions
- HPV InfectionHPV-Related Cervical Carcinoma
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-04-26
- Last Posted Date
- 2025-02-14
- Lead Sponsor
- BlueSky Immunotherapies GmbH
- Target Recruit Count
- 20
- Registration Number
- NCT05829629
- Locations
- 🇸🇰
Univerzitná nemocnica Bratislava, Bratislava, Slovakia
BS-FU01 Follow-Up Study of FluBHPVE6E7 Study Subjects
Completed
- Conditions
- Safety IssuesHPV Infection
- First Posted Date
- 2020-08-27
- Last Posted Date
- 2025-02-13
- Lead Sponsor
- BlueSky Immunotherapies GmbH
- Target Recruit Count
- 25
- Registration Number
- NCT04528407
- Locations
- 🇦🇹
University of Vienna, Vienna, Austria
Study of FluBHPVE6E7 in HPV-16 Infected Women
Phase 1
Completed
- Conditions
- HPV Infection
- First Posted Date
- 2020-07-29
- Last Posted Date
- 2023-06-26
- Lead Sponsor
- BlueSky Immunotherapies GmbH
- Target Recruit Count
- 28
- Registration Number
- NCT04490512
- Locations
- 🇦🇹
Medical University of Vienna, Vienna, Austria
News
No news found